Your browser is no longer supported. Please, upgrade your browser.
SAVA [NASD]
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.55 Insider Own1.90% Shs Outstand39.96M Perf Week15.52%
Market Cap2.04B Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float37.46M Perf Month25.44%
Income-20.80M PEG- EPS next Q-0.33 Inst Own30.00% Short Float30.30% Perf Quarter-4.08%
Sales- P/S- EPS this Y8.80% Inst Trans10.37% Short Ratio1.32 Perf Half Y3.78%
Book/sh6.70 P/B8.35 EPS next Y25.40% ROA-8.90% Target Price159.25 Perf Year626.75%
Cash/sh6.63 P/C8.44 EPS next 5Y- ROE-9.10% 52W Range6.70 - 146.16 Perf YTD720.53%
Dividend- P/FCF- EPS past 5Y35.40% ROI- 52W High-61.71% Beta0.51
Dividend %- Quick Ratio39.80 Sales past 5Y- Gross Margin- 52W Low735.22% ATR8.03
Employees11 Current Ratio39.80 Sales Q/Q- Oper. Margin- RSI (14)47.76 Volatility11.52% 16.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-317.90% Profit Margin- Rel Volume0.22 Prev Close58.05
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume8.63M Price55.96
Recom2.00 SMA20-9.49% SMA50-1.09% SMA200-11.48% Volume1,937,628 Change-3.60%
Jul-15-21Downgrade Cantor Fitzgerald Overweight → Neutral $100
Jul-07-21Reiterated Maxim Group Buy $80 → $190
Apr-27-21Initiated B. Riley Securities Buy $78
Feb-16-21Reiterated H.C. Wainwright Buy $20 → $66
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Nov-27-21 01:18PM  
Nov-26-21 09:34AM  
Nov-22-21 11:00AM  
Nov-19-21 08:59AM  
Nov-18-21 02:27PM  
10:36AM  
09:15AM  
08:43AM  
06:04AM  
Nov-17-21 04:55PM  
04:40PM  
04:04PM  
02:27PM  
01:14PM  
09:32AM  
08:12AM  
08:00AM  
04:53AM  
Nov-15-21 11:33AM  
09:00AM  
Nov-11-21 04:08PM  
12:11PM  
07:44AM  
Nov-10-21 12:53PM  
09:00AM  
Nov-09-21 09:40PM  
11:51AM  
09:16AM  
Nov-04-21 05:24PM  
04:01PM  
02:04PM  
09:30AM  
09:02AM  
06:38AM  
Nov-03-21 03:08PM  
Nov-02-21 09:00PM  
Nov-01-21 11:32AM  
06:00AM  
06:00AM  
Oct-29-21 04:34PM  
02:30PM  
Oct-28-21 05:45PM  
Oct-26-21 07:46PM  
05:50PM  
02:40PM  
01:10PM  
12:05PM  
10:30AM  
10:00AM  
09:57AM  
09:15AM  
07:45AM  
05:20AM  
Oct-25-21 11:01PM  
06:18PM  
05:02PM  
04:48PM  
03:36PM  
02:40PM  
01:42PM  
01:41PM  
12:45PM  
12:05PM  
11:00AM  
09:41AM  
08:04AM  
05:40AM  
Oct-24-21 11:50PM  
09:20PM  
03:09PM  
01:00PM  
08:29AM  
08:29AM  
08:02AM  
06:34AM  
Oct-23-21 06:00PM  
11:15AM  
11:00AM  
09:30AM  
08:03AM  
Oct-22-21 10:50PM  
10:50PM  
07:30PM  
05:52PM  
04:30PM  
03:15PM  
02:45PM  
11:40AM  
11:30AM  
11:00AM  
10:16AM  
09:15AM  
09:00AM  
07:50AM  
Oct-21-21 10:35PM  
06:48PM  
04:11PM  
02:44PM  
12:30PM  
10:00AM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUSSIN ROBERT ZDirectorSep 15Option Exercise27.372,80176,6636,710Sep 21 04:01 PM
BARBIER REMIPresident and CEOJul 20Option Exercise20.232,80156,664326,652Jul 20 05:21 PM
BARBIER REMIPresident and CEOMay 27Option Exercise53.5556,0303,000,4061,134,885May 28 04:01 PM
ROBERTSON SANFORDDirectorMar 30Option Exercise40.897,472305,521920,095Mar 31 09:14 PM
FRIEDMANN NADAVChief Medical OfficerMar 17Option Exercise53.5528,0151,500,20392,428Mar 18 04:06 PM
O DONNELL MICHAEL JDirectorMar 16Option Exercise49.004,669228,7819,257Mar 18 03:59 PM